Your browser doesn't support javascript.
loading
A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity.
Bardelli, Marco; Frontzek, Karl; Simonelli, Luca; Hornemann, Simone; Pedotti, Mattia; Mazzola, Federica; Carta, Manfredi; Eckhardt, Valeria; D'Antuono, Rocco; Virgilio, Tommaso; González, Santiago F; Aguzzi, Adriano; Varani, Luca.
Afiliación
  • Bardelli M; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Frontzek K; Institute of Neuropathology, University of Zurich, Zurich, Switzerland.
  • Simonelli L; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Hornemann S; Institute of Neuropathology, University of Zurich, Zurich, Switzerland.
  • Pedotti M; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Mazzola F; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Carta M; Institute of Neuropathology, University of Zurich, Zurich, Switzerland.
  • Eckhardt V; Institute of Neuropathology, University of Zurich, Zurich, Switzerland.
  • D'Antuono R; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Virgilio T; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • González SF; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Aguzzi A; Institute of Neuropathology, University of Zurich, Zurich, Switzerland.
  • Varani L; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
PLoS Pathog ; 14(10): e1007335, 2018 10.
Article en En | MEDLINE | ID: mdl-30273408
ABSTRACT
Antibodies to the prion protein, PrP, represent a promising therapeutic approach against prion diseases but the neurotoxicity of certain anti-PrP antibodies has caused concern. Here we describe scPOM-bi, a bispecific antibody designed to function as a molecular prion tweezer. scPOM-bi combines the complementarity-determining regions of the neurotoxic antibody POM1 and the neuroprotective POM2, which bind the globular domain (GD) and flexible tail (FT) respectively. We found that scPOM-bi confers protection to prion-infected organotypic cerebellar slices even when prion pathology is already conspicuous. Moreover, scPOM-bi prevents the formation of soluble oligomers that correlate with neurotoxic PrP species. Simultaneous targeting of both GD and FT was more effective than concomitant treatment with the individual molecules or targeting the tail alone, possibly by preventing the GD from entering a toxic-prone state. We conclude that simultaneous binding of the GD and flexible tail of PrP results in strong protection from prion neurotoxicity and may represent a promising strategy for anti-prion immunotherapy.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Priones / Cerebelo / Enfermedades por Prión / Anticuerpos Biespecíficos / Proteínas Priónicas / Inmunoterapia Límite: Animals Idioma: En Revista: PLoS Pathog Año: 2018 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Priones / Cerebelo / Enfermedades por Prión / Anticuerpos Biespecíficos / Proteínas Priónicas / Inmunoterapia Límite: Animals Idioma: En Revista: PLoS Pathog Año: 2018 Tipo del documento: Article País de afiliación: Suiza